Log in to save to my catalogue
Log in to save to my catalogue

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Bre...

| Ask | Become a Library member

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Bre...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6947627

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

About this item

Publication information

Publisher

Switzerland: MDPI

Subjects

Subjects and topics

More information

Scope and Contents

Contents

The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor recurrence. We explored the therapeutic potential of adding neoadjuvant metformin as an innovative strategy to decrease the proliferative potential of residual BC cells in patients failing to achi...

Alternative Titles

Full title

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6947627

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6947627

Other Identifiers

ISSN

2077-0383

E-ISSN

2077-0383

DOI

10.3390/jcm8122180

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections